The new prophylactic HPV vaccines consist of virus-like particles self-assembled from recombinantly expressed L1 major capsid protein. Due to the absence of potentially oncogenic viral DNA, they have been proven safe and well tolerated in thousands of vaccinated individuals. Prophylactic HPV vaccination has demonstrated 100% efficacy in preventing type-specific persistent infections and associated genital dysplasias.